S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
How the Wealthy Elite are Picking Stocks (Ad)pixel
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
3 Safe Earnings Plays for a Risk-Off Market
How the Wealthy Elite are Picking Stocks (Ad)pixel
Micron to bring microchip plant to upstate New York
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Stocks rise in extended rally, clawing back more ground
Live Updates: Russia-Ukraine War
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
How the Wealthy Elite are Picking Stocks (Ad)pixel
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
3 Safe Earnings Plays for a Risk-Off Market
How the Wealthy Elite are Picking Stocks (Ad)pixel
Micron to bring microchip plant to upstate New York
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Stocks rise in extended rally, clawing back more ground
Live Updates: Russia-Ukraine War
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
How the Wealthy Elite are Picking Stocks (Ad)pixel
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
3 Safe Earnings Plays for a Risk-Off Market
How the Wealthy Elite are Picking Stocks (Ad)pixel
Micron to bring microchip plant to upstate New York
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Stocks rise in extended rally, clawing back more ground
Live Updates: Russia-Ukraine War
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
How the Wealthy Elite are Picking Stocks (Ad)pixel
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
3 Safe Earnings Plays for a Risk-Off Market
How the Wealthy Elite are Picking Stocks (Ad)pixel
Micron to bring microchip plant to upstate New York
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Stocks rise in extended rally, clawing back more ground
Live Updates: Russia-Ukraine War
NASDAQ:BEAM

Beam Therapeutics - BEAM Stock Forecast, Price & News

$51.60
+3.71 (+7.75%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
$49.36
$52.20
50-Day Range
$46.56
$70.31
52-Week Range
$27.77
$100.06
Volume
977,472 shs
Average Volume
1.20 million shs
Market Capitalization
$3.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.67

Beam Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
69.9% Upside
$87.67 Price Target
Short Interest
Bearish
22.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of Beam Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3.20 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.74) to ($5.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.53 out of 5 stars

Medical Sector

1008th out of 1,087 stocks

Biological Products, Except Diagnostic Industry

163rd out of 169 stocks

BEAM stock logo

About Beam Therapeutics (NASDAQ:BEAM) Stock

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BEAM Stock News Headlines

Sell every Stock except ONE
Markets are down... But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Gene Therapy Biotech Prime Medicine Begins U.S. IPO Effort
Sell every Stock except ONE
Markets are down... But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Arch, a16z back Alnylam co-founder's next big RNA play
Recap: Beam Therapeutics Q2 Earnings
Beam Therapeutics Inc. Q2 Loss decreases, beats estimates
See More Headlines
Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BEAM Company Calendar

Last Earnings
8/09/2022
Today
10/05/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BEAM
Fax
N/A
Employees
341
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$87.67
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+69.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-370,640,000.00
Net Margins
-304.21%
Pretax Margin
-304.21%

Debt

Sales & Book Value

Annual Sales
$51.84 million
Book Value
$12.13 per share

Miscellaneous

Free Float
67,541,000
Market Cap
$3.63 billion
Optionable
Not Optionable
Beta
1.82

Key Executives

  • Mr. John M. Evans M.B.A.Mr. John M. Evans M.B.A. (Age 44)
    CEO & Director
    Comp: $1.02M
  • Dr. Giuseppe Ciaramella Ph.D.Dr. Giuseppe Ciaramella Ph.D. (Age 53)
    Pres & Chief Scientific Officer
    Comp: $890.79k
  • Ms. Terry-Ann Burrell M.B.A.Ms. Terry-Ann Burrell M.B.A. (Age 45)
    CFO & Treasurer
    Comp: $687.52k
  • Dr. Feng Zhang Ph.D.
    Co-Founder
  • Dr. David R. Liu Ph.D.
    Co-Founder
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder
  • Dr. Nicole Gaudelli Ph.D.
    Co-Founder
  • Dr. Alexis Komor Ph.D.
    Co-Founder
  • Ms. Suzanne Fleming (Age 61)
    Chief Accounting Officer
  • Mr. Brian Riley (Age 45)
    Sr. VP of Technical Operations













BEAM Stock - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BEAM shares.
View BEAM analyst ratings
or view top-rated stocks.

What is Beam Therapeutics' stock price forecast for 2022?

6 brokers have issued twelve-month target prices for Beam Therapeutics' stock. Their BEAM share price forecasts range from $60.00 to $130.00. On average, they anticipate the company's share price to reach $87.67 in the next year. This suggests a possible upside of 69.9% from the stock's current price.
View analysts price targets for BEAM
or view top-rated stocks among Wall Street analysts.

How have BEAM shares performed in 2022?

Beam Therapeutics' stock was trading at $79.69 at the beginning of the year. Since then, BEAM stock has decreased by 35.2% and is now trading at $51.60.
View the best growth stocks for 2022 here
.

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our BEAM earnings forecast
.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) released its quarterly earnings results on Tuesday, August, 9th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.08) by $0.06. The firm earned $16.65 million during the quarter, compared to analysts' expectations of $9.44 million. Beam Therapeutics had a negative net margin of 304.21% and a negative trailing twelve-month return on equity of 27.45%. The company's revenue was up 277433.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.23) EPS.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Beam Therapeutics' stock symbol?

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Beam Therapeutics' stock price today?

One share of BEAM stock can currently be purchased for approximately $51.60.

How much money does Beam Therapeutics make?

Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $3.63 billion and generates $51.84 million in revenue each year. The company earns $-370,640,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis.

How many employees does Beam Therapeutics have?

The company employs 341 workers across the globe.

How can I contact Beam Therapeutics?

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at investors@beamtx.com.

This page (NASDAQ:BEAM) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.